BRPI0920706B8 - partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica - Google Patents

partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica

Info

Publication number
BRPI0920706B8
BRPI0920706B8 BRPI0920706A BRPI0920706A BRPI0920706B8 BR PI0920706 B8 BRPI0920706 B8 BR PI0920706B8 BR PI0920706 A BRPI0920706 A BR PI0920706A BR PI0920706 A BRPI0920706 A BR PI0920706A BR PI0920706 B8 BRPI0920706 B8 BR PI0920706B8
Authority
BR
Brazil
Prior art keywords
tiotropium
inhalable particles
preparing
pharmaceutical composition
same
Prior art date
Application number
BRPI0920706A
Other languages
English (en)
Inventor
Sereno Guerra Antonio
Amighi Karim
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40348057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920706(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of BRPI0920706A2 publication Critical patent/BRPI0920706A2/pt
Publication of BRPI0920706B1 publication Critical patent/BRPI0920706B1/pt
Publication of BRPI0920706B8 publication Critical patent/BRPI0920706B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Electrolytic Production Of Metals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica a presente invenção refere-se a partículas inaláveis compreendendo uma forma amorfa estabilizada de tiotrópio, com um agente de estabilização, e a essas partículas opcionalmente misturadas com um ou mais excipientes grossos. ela também se refere a partículas inaláveis que compreendem uma forma amorfa estabilizada de tiotrópio com um agente de estabilização misturada com um ou mais excipientes grossos, que tenham um tamanho médio de partícula de 15 a 250 mm. ela também se refere a uma composição farmacêutica que compreenda as partículas inaláveis da invenção, a um processo para a preparação das mesmas, e ao uso das mesmas para a preparação de um medicamento para o tratamento de asma ou da doença pulmonar obstrutora crônica (copd).
BRPI0920706A 2008-10-02 2009-10-02 partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica BRPI0920706B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08382040A EP2172190A1 (en) 2008-10-02 2008-10-02 Inhalable particles comprising tiotropium
EP08382040.7 2008-10-02
US10411308P 2008-10-09 2008-10-09
US61/104,113 2008-10-09
PCT/EP2009/062821 WO2010037845A1 (en) 2008-10-02 2009-10-02 Inhalable particles comprising tiotropium

Publications (3)

Publication Number Publication Date
BRPI0920706A2 BRPI0920706A2 (pt) 2015-12-29
BRPI0920706B1 BRPI0920706B1 (pt) 2021-02-02
BRPI0920706B8 true BRPI0920706B8 (pt) 2021-05-25

Family

ID=40348057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920706A BRPI0920706B8 (pt) 2008-10-02 2009-10-02 partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica

Country Status (39)

Country Link
US (1) US20110311618A1 (pt)
EP (2) EP2172190A1 (pt)
JP (1) JP5622730B2 (pt)
KR (1) KR101639089B1 (pt)
CN (1) CN102170861B (pt)
AR (1) AR073528A1 (pt)
AU (1) AU2009299801B2 (pt)
BR (1) BRPI0920706B8 (pt)
CA (1) CA2737399C (pt)
CL (1) CL2011000696A1 (pt)
CO (1) CO6361899A2 (pt)
CR (1) CR20110227A (pt)
CY (1) CY1121090T1 (pt)
DK (1) DK2349204T3 (pt)
DO (1) DOP2011000091A (pt)
EC (1) ECSP11010925A (pt)
ES (1) ES2675857T3 (pt)
HN (1) HN2011000864A (pt)
HR (1) HRP20181009T1 (pt)
HU (1) HUE038208T2 (pt)
LT (1) LT2349204T (pt)
MA (1) MA34560B1 (pt)
MX (1) MX2011003491A (pt)
MY (1) MY159172A (pt)
NI (1) NI201100066A (pt)
NZ (1) NZ591923A (pt)
PE (2) PE20142435A1 (pt)
PL (1) PL2349204T3 (pt)
PT (1) PT2349204T (pt)
RU (2) RU2685236C2 (pt)
SI (1) SI2349204T1 (pt)
SM (1) SMT201800350T1 (pt)
SV (1) SV2011003852A (pt)
TR (1) TR201808269T4 (pt)
TW (1) TWI433675B (pt)
UA (1) UA100777C2 (pt)
UY (1) UY32160A (pt)
WO (1) WO2010037845A1 (pt)
ZA (1) ZA201101735B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552414A4 (en) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION
EP2575786B1 (en) * 2010-06-03 2017-11-15 Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. Process for dry powder formulations
WO2011154014A1 (en) * 2010-06-11 2011-12-15 Gea Process Engineering A/S Controlled humidity drying
NZ607358A (en) 2010-08-23 2015-04-24 Takeda Gmbh Humidified particles comprising a therapeutically active substance
WO2013109216A2 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising tiotropium
US9387616B2 (en) 2012-08-03 2016-07-12 Otto Männer Innovation GmbH Hot runner injection molding apparatus with additional controller
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CN109789131B (zh) * 2016-09-19 2022-08-26 墨西哥氟石股份公司 药物组合物
EP4108230A1 (en) * 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation
GR1010358B (el) * 2021-09-14 2022-12-16 Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, Σταθερο φαρμακευτικο σκευασμα που περιεχει βρωμιουχο τιοτροπιο, για χορηγηση απο το αναπνευστικο
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
AP1712A (en) 2000-10-12 2007-01-24 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
EP1591121B1 (en) * 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form
US6485279B2 (en) * 2000-12-26 2002-11-26 Carrier Corporation Thrust load reliever
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2478974C (en) * 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
PT1869035E (pt) * 2005-12-19 2013-01-10 Sicor Inc Novas formas de brometo de tiotrópio e processos para sua preparação
EP1976486A1 (en) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations

Also Published As

Publication number Publication date
NZ591923A (en) 2012-02-24
WO2010037845A1 (en) 2010-04-08
EP2172190A1 (en) 2010-04-07
CN102170861A (zh) 2011-08-31
BRPI0920706B1 (pt) 2021-02-02
PE20142435A1 (es) 2015-01-11
TWI433675B (zh) 2014-04-11
EP2349204A1 (en) 2011-08-03
DOP2011000091A (es) 2011-04-30
PT2349204T (pt) 2018-07-06
MX2011003491A (es) 2011-06-16
EP2349204B1 (en) 2018-04-11
MY159172A (en) 2016-12-30
RU2014150986A3 (pt) 2018-07-02
SI2349204T1 (en) 2018-08-31
RU2685236C2 (ru) 2019-04-17
AU2009299801B2 (en) 2014-02-27
KR101639089B1 (ko) 2016-07-12
ES2675857T3 (es) 2018-07-13
DK2349204T3 (en) 2018-07-16
CR20110227A (es) 2011-06-24
CA2737399A1 (en) 2010-04-08
RU2011117256A (ru) 2012-11-10
HN2011000864A (es) 2015-02-09
NI201100066A (es) 2012-01-05
TR201808269T4 (tr) 2018-07-23
UA100777C2 (ru) 2013-01-25
HUE038208T2 (hu) 2018-10-29
UY32160A (es) 2010-04-30
BRPI0920706A2 (pt) 2015-12-29
AU2009299801A1 (en) 2010-04-08
MA34560B1 (fr) 2013-10-02
LT2349204T (lt) 2018-10-10
KR20110081265A (ko) 2011-07-13
CL2011000696A1 (es) 2011-07-29
CN102170861B (zh) 2014-05-14
CA2737399C (en) 2017-02-21
JP5622730B2 (ja) 2014-11-12
HRP20181009T1 (hr) 2018-08-24
AR073528A1 (es) 2010-11-10
ZA201101735B (en) 2012-05-30
JP2012504580A (ja) 2012-02-23
SV2011003852A (es) 2011-04-12
PE20110850A1 (es) 2011-11-25
RU2014150986A (ru) 2015-06-10
ECSP11010925A (es) 2011-07-29
US20110311618A1 (en) 2011-12-22
CY1121090T1 (el) 2019-12-11
TW201018468A (en) 2010-05-16
SMT201800350T1 (it) 2018-09-13
PL2349204T3 (pl) 2018-09-28
CO6361899A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
ECSP11010925A (es) Partículas inhalables que comprenden tiotropio
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
BR112013001119A2 (pt) composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
MX373699B (es) Composicion farmaceutica que contiene budesonida y formoterol.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
BR112016002222A2 (pt) partículas inaláveis compreendendo tiotrópio e indacaterol
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
BR112015015483A2 (pt) forma farmacêutica monolítica para a liberação modificada de uma combinação de ingredientes ativos
BR112015004810A2 (pt) preparações de tiotrópio
WO2010003465A3 (en) A drug powder for inhalation administration and a process thereof
TN2011000121A1 (en) Inhalable particles comprising tiotropium
MX372705B (es) Composición farmacéutica que contiene budesonida y formoterol
HK1189158B (en) Pharmaceutical composition
HK1189158A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF